• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India.吸烟、饮酒及其他导致有症状新冠病毒病与无症状严重急性呼吸综合征冠状病毒2感染的风险因素:一项来自印度拉贾斯坦邦西部的病例对照研究
Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.
2
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.南非印度马杜赖市首次新冠疫情期间的 SARS-CoV-2 感染和死亡率:一项前瞻性、主动监测研究。
Lancet Infect Dis. 2021 Dec;21(12):1665-1676. doi: 10.1016/S1473-3099(21)00393-5. Epub 2021 Aug 13.
3
COVID-19 Outcome and Tobacco Product Use: Case-Control and Retrospective Cohort Studies Using Nationwide Samples.COVID-19 结局与烟草产品使用:基于全国样本的病例对照和回顾性队列研究。
J Korean Med Sci. 2024 Mar 25;39(11):e103. doi: 10.3346/jkms.2024.39.e103.
4
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.
5
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3.
6
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.巴西原住民中由严重急性呼吸综合征冠状病毒2感染或其他病原体引起的严重急性呼吸综合征:一项关于冠状病毒病(COVID)-19大流行第一年的观察性研究。
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
8
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
9
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.《104 名“钻石公主”号邮轮上 SARS-CoV-2 感染患者的 COVID-19 临床特征:一项回顾性分析》。
Lancet Infect Dis. 2020 Sep;20(9):1043-1050. doi: 10.1016/S1473-3099(20)30482-5. Epub 2020 Jun 12.
10
A preliminary study on contact tracing & transmission chain in a cluster of 17 cases of severe acute respiratory syndrome coronavirus 2 infection in Basti, Uttar Pradesh, India.印度北方邦巴斯蒂 17 例严重急性呼吸综合征冠状病毒 2 感染聚集性病例的接触者追踪和传播链初步研究。
Indian J Med Res. 2020;152(1 & 2):95-99. doi: 10.4103/ijmr.IJMR_2914_20.

引用本文的文献

1
Spectrum of COVID-19 cases in Arkhangelsk, Northwest Russia: Findings from a population-based study linking serosurvey, registry data, and self-reports of symptoms.俄罗斯西北部阿尔汉格尔斯克地区 COVID-19 病例谱:一项基于人群的研究的发现,该研究将血清学调查、登记数据和症状自我报告联系起来。
PLoS One. 2024 Oct 11;19(10):e0311287. doi: 10.1371/journal.pone.0311287. eCollection 2024.
2
Prevalence and association between alcohol, tobacco, and COVID-19: a study from a tribal predominant district in eastern India.酒精、烟草与 COVID-19 之间的流行情况及关联:来自印度东部一个以部落为主的地区的研究。
Front Public Health. 2024 Aug 16;12:1415178. doi: 10.3389/fpubh.2024.1415178. eCollection 2024.
3
Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.评估门诊患者中熊去氧胆酸对新型冠状病毒肺炎的保护效果及危险因素。
Front Pharmacol. 2024 Jul 31;15:1381830. doi: 10.3389/fphar.2024.1381830. eCollection 2024.
4
Association of Alcohol Use with COVID-19 Infection and Hospitalization Among People Living with HIV in the United States, 2020.美国 HIV 感染者中酒精使用与 COVID-19 感染和住院的关联,2020 年。
AIDS Behav. 2024 May;28(5):1795-1807. doi: 10.1007/s10461-024-04301-6. Epub 2024 Feb 29.
5
Spatio-temporal epidemiology and associated indicators of COVID-19 (wave-I and II) in India.印度 COVID-19(第一波和第二波)的时空流行病学及相关指标。
Sci Rep. 2024 Jan 2;14(1):220. doi: 10.1038/s41598-023-50363-2.
6
Unintended Consequences of COVID-19 Non-Pharmaceutical Interventions (NPIs) for Population Health and Health Inequalities.COVID-19 非药物干预(NPIs)对人口健康和健康不平等的意外后果。
Int J Environ Res Public Health. 2023 Mar 23;20(7):5223. doi: 10.3390/ijerph20075223.
7
The role of smoking in COVID-19 progression: a comprehensive meta-analysis.吸烟在 COVID-19 进展中的作用:一项综合荟萃分析。
Eur Respir Rev. 2023 Mar 8;32(167). doi: 10.1183/16000617.0191-2022. Print 2023 Mar 31.
8
Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study.无症状与有症状的新型冠状病毒感染:一项横断面血清流行率研究。
Trop Med Health. 2022 Dec 27;50(1):98. doi: 10.1186/s41182-022-00490-9.
9
Lower SARS-CoV-2 household transmission in children and adolescents compared to adults.与成年人相比,儿童和青少年家庭中 SARS-CoV-2 的传播率较低。
Sci Rep. 2022 Dec 27;12(1):22453. doi: 10.1038/s41598-022-24643-2.
10
Repeated ethanol exposure and withdrawal alters angiotensin-converting enzyme 2 expression in discrete brain regions: Implications for SARS-CoV-2 neuroinvasion.反复乙醇暴露和戒断会改变不同脑区血管紧张素转换酶 2 的表达:对 SARS-CoV-2 神经入侵的影响。
Alcohol Clin Exp Res (Hoboken). 2023 Feb;47(2):219-239. doi: 10.1111/acer.15000. Epub 2023 Jan 1.

本文引用的文献

1
Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与地方性和季节性β冠状病毒的血清学交叉反应性
J Clin Immunol. 2021 Jul;41(5):906-913. doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.
2
Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的交叉反应:低致病性人类冠状病毒的潜在作用。
Lancet Microbe. 2020 Aug;1(4):e151. doi: 10.1016/S2666-5247(20)30098-7. Epub 2020 Aug 6.
3
Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance.2019冠状病毒病大流行时代的尼古丁治疗与戒烟:一个有趣的联盟。
ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00306-2020. eCollection 2020 Jul.
4
Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases.推断 SARS-CoV-2 的传染期:对无症状和有症状 COVID-19 病例的现有证据进行快速范围审查和分析。
BMJ Open. 2020 Aug 5;10(8):e039856. doi: 10.1136/bmjopen-2020-039856.
5
A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications.一种与 COVID-19 相关的烟碱能假说及其预防和治疗意义。
C R Biol. 2020 Jun 5;343(1):33-39. doi: 10.5802/crbiol.8.
6
The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.宿主遗传学在 SARS-CoV-2 免疫反应和 COVID-19 易感性及严重程度中的作用。
Immunol Rev. 2020 Jul;296(1):205-219. doi: 10.1111/imr.12897. Epub 2020 Jul 13.
7
Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice.吸烟、严重急性呼吸综合征冠状病毒2与冠状病毒病2019:关于对公共卫生政策与实践影响的综述之综述
Tob Induc Dis. 2020 Jul 3;18:58. doi: 10.18332/tid/124788. eCollection 2020.
8
Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis.住院COVID-19患者中的当前吸烟、既往吸烟与不良结局:一项系统评价和荟萃分析
Ther Adv Chronic Dis. 2020 Jun 25;11:2040622320935765. doi: 10.1177/2040622320935765. eCollection 2020.
9
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
10
Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.静默性低氧血症:COVID-19 患者临床恶化的先兆。
Am J Emerg Med. 2020 Oct;38(10):2243.e5-2243.e6. doi: 10.1016/j.ajem.2020.05.044. Epub 2020 May 22.

吸烟、饮酒及其他导致有症状新冠病毒病与无症状严重急性呼吸综合征冠状病毒2感染的风险因素:一项来自印度拉贾斯坦邦西部的病例对照研究

Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India.

作者信息

Saurabh Suman, Verma Mahendra Kumar, Gautam Vaishali, Kumar Nitesh, Jain Vidhi, Goel Akhil Dhanesh, Gupta Manoj Kumar, Sharma Prem Prakash, Bhardwaj Pankaj, Singh Kuldeep, Nag Vijaya Lakshmi, Garg Mahendra Kumar, Misra Sanjeev

机构信息

Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.

Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.

出版信息

Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.

DOI:10.1093/trstmh/traa172
PMID:33444432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7928693/
Abstract

BACKGROUND

Understanding risk factors of symptomatic coronavirus disease 2019 (COVID-19) vis-à-vis asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, severe disease and death is important.

METHODS

An unmatched case-control study was conducted through telephonic interviews among individuals who tested positive for SARS-CoV-2 in Jodhpur, India from 23 March to 20 July 2020. Contact history, comorbidities and tobacco and alcohol use were elicited using standard tools.

RESULTS

Among 911 SARS-CoV-2-infected individuals, 47.5% were symptomatic, 14.1% had severe COVID-19 and 41 (4.5%) died. Older age, working outside the home, cardiac and respiratory comorbidity and alcohol use were found to increase the risk of symptomatic disease as compared with asymptomatic infection. Current tobacco smoking (odds ratio [OR] 0.46 [95% confidence interval {CI} 0.26 to 0.78]) but not smokeless tobacco use (OR 0.81 [95% CI 0.55 to 1.19]) appeared to reduce the risk of symptomatic disease. Age ≥60 y and renal comorbidity were significantly associated with severe COVID-19. Age ≥60 y and respiratory and cardiac comorbidity were found to predispose to mortality.

CONCLUSIONS

The apparent reduced risk of symptomatic COVID-19 among tobacco smokers could be due to residual confounding owing to unknown factors, while acknowledging the limitation of recall bias. Cross-protection afforded by frequent upper respiratory tract infection among tobacco smokers could explain why a similar association was not found for smokeless tobacco use, thereby being more plausible than the 'nicotinic hypothesis'. Those with comorbidities and age ≥60 y should be prioritized for hospital admission.

摘要

背景

了解2019冠状病毒病(COVID-19)症状性感染相对于无症状严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染、重症疾病和死亡的风险因素很重要。

方法

通过电话访谈对2020年3月23日至7月20日在印度焦特布尔SARS-CoV-2检测呈阳性的个体进行了一项非匹配病例对照研究。使用标准工具获取接触史、合并症以及烟草和酒精使用情况。

结果

在911名感染SARS-CoV-2的个体中,47.5%有症状,14.1%患有重症COVID-19,41人(4.5%)死亡。与无症状感染相比,年龄较大、外出工作、心脏和呼吸系统合并症以及饮酒会增加出现症状性疾病的风险。当前吸烟(比值比[OR]0.46[95%置信区间{CI}0.26至0.78])而非使用无烟烟草(OR 0.81[95%CI 0.55至1.19])似乎会降低出现症状性疾病的风险。年龄≥60岁和肾脏合并症与重症COVID-19显著相关。年龄≥60岁以及呼吸系统和心脏合并症易导致死亡。

结论

吸烟者中COVID-19症状性感染风险明显降低可能是由于未知因素导致的残余混杂,同时承认存在回忆偏倚的局限性。吸烟者频繁的上呼吸道感染所提供的交叉保护可以解释为什么无烟烟草使用未发现类似关联,因此比“尼古丁假说”更具合理性。合并症患者和年龄≥60岁的患者应优先住院治疗。